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Abstract  
 
         Hepatitis  C  virus  (HCV)  infection  increases  morbimortality  in  renal  transplantation. 
Hepatitis C virus positive kidney transplant candidates who remain on the waiting list show a 
greater risk of mortality than those who are  transplanted. The aim of this study was to examine 
the  impact  of  HCV  infection  on  patient  and  allograft  survival  after  kidney  transplantation. 
Eighty  two  patients  with  end  stage  renal  disease  underwent  kidney  transplantation  were 
included  in  this  study.  The  patients  were  classified  into  group  I  including  46  HCV  negative 
patients  (HCV-)  and  group  II  including  36  HCV  antibody  and  HCV-RNA  positive  patients 
(HCV+).  The  immunosuppressive  protocols  were  similar  in  both  groups.  All  recipients  were 
followed  up  for  3years.Results:  There  were  statistically  insignificant  differences  (P>0.05) 
between  both  groups  as  regard  age,  gender  and  donor  type  (living  related  or  unrelated). 
Hemodialysis  duration  before  transplantation  was  highly  significant  (P<  0.01)  longer  among 
HCV+ group (4.9± 3.7 years) compared to  HCV- patients (2.4± 4.3 years).One patient  died 
from each group showing insignificant difference (P>0.05); 2 grafts (4.3%) lost in HCV- group 
and  3  (8.3%)  in  HCV+  group  with  also  insignificant  difference  (P>0.05).  Five  recipients 
(10.9%) in group I experienced delayed graft function compared to 2 (5.6%) recipients in group 
II with statistically insignificant difference. There was a significantly (P< 0.05) more number of 
acute rejection episodes among HCV+ patients (11=30.6%) than HCV- patients (5=10.9%).New 
onset  diabetes  mellitus  occurred  more  among  HCV+  (19.4%)  than  HCV-  (8.7%)  recipients, 
however the difference was insignificant. There was a significant (P<0.05) higher incidence of 
cytomegalovirus disease among HCV+ (11.1%) than HCV- (2.2%) recipients. Conclusion: This 
study  suggested  that  HCV  positivity  does  not  significantly  affect  patient  and  graft  survival 
despite  the  significant  increased  incidence  of  acute  rejection  episodes  and  cytomegalovirus 
disease.  Lastly,  all  measures  should  be  taken  to  prevent  HCV  transmission  in  dialysis 
population.  
      
Introduction  
         
         Since  hepatitis  C  virus  (HCV)  was 
identified in 1989 by Choo et al, as a main 
cause  of  non-A  non  -B  hepatitis,  HCV 
infection has achieved a great relevance  in 
nephrology  on  the  basis  of  its  high 
prevalence  among  dialysis  patients,  renal 
allograft  recipients  as  well  as  in  essential 
mixed  cryoglobulinemia  with  associated 
membranoproliferative    glomerulonephr-
itis
(1,2,3).  Renal  transplantation  confers  an 
overall  survival  benefit  in  HCV  + 
hemodialysis  patients  with  similar  5-year 
patients and graft survival to those without 
HCV infection
(4). Unfortunately, there is no 
safe treatment for HCV infection after renal 
transplantation.  It  has  been  reported  rece-
ntly   that     ribavirin    monotherapy  impr-
oved liver enzymes levels, had no effect on 
HCV viremia, but seems also not to have a 
beneficial effect on liver fibrosis 
(5). 
 
Aim Of The Work   
 
         The aim of this study was to evaluate 
the  effect  of  HCV  infection  among  end 
stage  renal  disease  (ESRD)  patients  after 
undergoing kidney transplantation.  
 
Patients And Methods 
 
         This  prospective  study  included  82 
patients  with  ESRD.  All  were  receiving 
their first living kidney transplants at Naser 
Institute,  and  Ain  Shams  University 
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Specialized  Hospital.  The  patients  were 
classified  according  to  HCV  status  into  2 
groups. Group I: included 46 HBs Ag, and 
HCV  antibody  negative  (HCV–)  patients, 
28 (60.9%) males and 18 (39.1%) females; 
31 (82.6%)  patients received  living  related 
grafts and the rest 14(17.4) were unrelated. 
Eight  patients  of  group  I  were  preemptive 
transplantation. Group II: Included 36 HBs 
Ag  negative  HCV  antibody  and  RNA 
positive patients, 20 (55.6%) males and 16 
(44.4%)  females,  30  (83.3%)  patients 
received  related  and  6  (16.7)  unrelated 
grafts. 
         All  patients  were  exposed  to  history 
taking  including  the  etiology  of  renal 
failure,  duration  on  hemodialysis,  blood 
transfusion,  and  antiviral  treatment  (in 
group  II).  All  patients  underwent  blood 
testing for serum alanine transferase (ALT), 
aspartate  transferase  (AST),  albumin, 
prothrombin  time,  creatinine,  blood  urea 
nitrogen  (BUN),  and  blood  glucose  level. 
Anti-HCV antibodies were determined with 
a  third  generation  enzyme  linked  immu-
noassay  (Abbott-laboratories,  Chicago,  IL, 
USA).HCV-RNA  was  detected  by  qualit-
ative  polymerase  chain  reaction  (PCR) 
using  Amplicor  Kits  (Roche  Diagnostic 
System,  Indianapolis,  USA).A  liver  biopsy 
was  indicated  for  all  HCV-RNA-  positive 
patients,  irrespective  of  transaminases 
levels. All recipients were having <4 HLA 
mismatch  with  their  donors,  and  the 
immunosuppressive  protocols  were  similar 
in both groups in the form of triple therapy 
with steroids, cyclosporine, and azathioprin. 
The patients were followed up for 3  years 
as regard renal function tests, liver function 
tests,  occurrence  of  delayed  graft  function 
(DGF)-defined as the transient requirement 
for dialysis beginning in the first week after 
the transplant  operation
(6)-,  acute  rejection, 
new  onset  diabetes  mellitus  (DM),  and 
cytomegalovirus disease.    
 
Statistical Methods 
 
          SPSS  statistical  software  package, 
v.9.02, Echosoft Corp, USA, 1998 was used 
for  data  analyze.  Dates  were  expressed  as 
Mean  ±SD  for  quantitative  measures  and 
both number and percentage for categorized 
data. Wilcoxon Rank sum test was used for 
comparison between two independent mean 
groups for non parametric data. Lastly, Chi- 
square  test  was  used  for  correlation 
between  each  2  independent  techniques. 
The  probability  of  error  at  0.05  was 
considered significant, while at 0.01 highly 
significant. 
 
Results 
  
         Table-1  shows  the  characteristics  of 
patients  in  group  I  (HCV-)  and  group  II 
(HCV+).  The  mean  age  in  group  I  was 
(42.4  ±  11.2  years)  with  non  significant 
difference  (P>0.05)  from  group  II  (44  ± 
10.5 years). Also, there was non significant 
difference  between  both  groups  as  regard 
gender (P> 0.05). Though 30.4% of patients 
in group I received kidneys from unrelated 
donors compared to 16.7% only in group II, 
the  difference  was  insignificant  (P>0.05). 
There  was  a  highly  significant  (P<0.01) 
longer  duration  of  hemodialysis  before 
transplantation in group II than group I (4.9 
± 3.7 & 2.4 ± 4.3 years respectively). 
  Table-2  Shows  non  significant  (P>0.05) 
difference between group I and group II as 
regard  serum  creatinine  level  during  the 
follow up period, while a highly significant 
(P<0.001) higher level of BUW in group II 
(38.2  ±11.7  mg/dl  )  compared  to  group  I      
( 21 ± 13.1 mg/dl ).One patient died in each 
group (both from infection) resulting in non 
significant  difference  (P>0.05)  in  patient 
survival  between  the  two  groups  after  3 
years,  and  the  relative  risk  was  1.3  with 
HCV  positivety.  Also,  there  was 
insignificant  difference  (P>0.05)  as  regard 
three  years  graft  survival  between  HCV  – 
(95.7%)  and  HCV  +  (91.7  %)  and  the 
relative risk of graft loss is 1.9 with HCV 
positively.  Five  recipients  (10.9%) 
experienced delayed graft function in group 
I compared to 11 recipients (5.6%) in group 
II  but  the  difference  was  insignificant 
(P>0.05).There  was  a  significant  (P<0.05) 
higher incidence of acute rejection episodes 
(all  were  steroid  sensitive)  in  group  II 
(30.6%)  than  group  I  (10.9%)  with  a 
relative  risk  of  2.8.  There  was  a  higher Impact of Hepatitis C Virus Infection on……. 
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incidence  of  new  onset  DM  in  group  II 
(19.4%) than group I (8.7%), however the 
difference was insignificant and the relative 
risk  of  developing  DM  with  HCV 
positively was 2.2.There was a significantly 
(P<0.05)  higher  incidence  of  cytome-
galovirus  disease  in  HCV+  group  II 
(11.1%)  in  comparison  to  group  I  (2.2%) 
with 5.1 relative risk.           
   
 
Table 1:    Patients Demographic  Characteristics,  and clinical  metrics  in group  I  (HCV-) 
and group II (HCV+).         
 
Parameter 
Group I  Group II 
Z  P-Value  Significance 
N = 46  N = 36 
Age (Years) mean ± SD  42.4  ±  11.2  44 ± 10.5  -0.7  >0.05  NS 
Gender 
Male  28 (60.9 % )  20 (55.6 %) 
0.63  >0.05  NS 
Female  18 (39.1 % )  16 (44.4 %) 
Donor Type 
LR  32 (69.6 %)  30 (83.3%) 
1.44  >0.05  NS 
LUR  14 (30.4 %)  6 (16.7%) 
Hemodialysis Duration (Years) mean ± SD  2.4 ± 4.3  4.9 ±  3.7  -2.8  <0.01  HS 
 
SD    : Standard deviation                       NS  : Non significant.  
LR    : Living related .                             HS  : Highly significant. 
LUR : Living unrelated 
 
 
Table 2: Patients and Graft survival during the follow up period (3 years) 
 
Parameter 
Group I  Group II 
Z  P-Value  Significance  RR 
N = 46  N = 36 
BUN (mg\dl) mean ± SD  21±13.1  38.2±11.7  -6.2  <0.001  HS   
S. Creatinine (mg\dl) mean ± SD  1.7± 1.1  1.8± 1.4  -0.4  >0.05  NS   
Death                                   n ( % )    1(2.2%)  1(2.8%)  -0.2  >0.05  NS  1.3 
Graft Failure                        n ( % )     2(4.3%)  3(8.3%)  -0.8  >0.05  NS  1.9 
Delayed Graft Function       n ( % )    5(10.9%)  2(5.6%)  0.85  >0.05  NS  2 
Acute Rejection                   n ( % )    5(10.9 %)  11(30.6%)  -2.2  <0.05  S  2.8 
Diabetes Mellitus                n ( % )                   4(8.7 %)  7(19.4%)  -1.4  >0.05  NS  2.2 
Cytomegalovirus Disease   n ( % )    1(2.2 %)  4(11.1 %)  -1.7  <0.05  S  5.1 
 
SD    : Standard deviation                        HS :  Highly significant                        
RR   :  Relative risk                                NS :  Non significant 
 
 
Discussion        
 
         This  study  showed  no  significant 
difference  between  both  groups  as  regard 
age,  gender,  and  donor  type.  There  was  a 
significant  longer  duration  of  hemodialysis 
before  transplantation  in  group  II  (HCV+) 
implicating  hemodialysis  in  the  prevalence 
of  HCV  among  ESRD  patients.  A  similar 
finding was reported by Bruchfeld et al
(7).           Yasser Soliman 
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The  present  study  showed  a  slightly 
increased incidence of patient mortality and 
graft  loss  in  HCV+  group  compared  to 
HCV- group  during the  3 years  follow  up 
period,  however  the  differences  were 
insignificant.  Pereira    study  showed  that 
graft  and  patient  survival  were  not 
significantly  different  after  3.5  years 
between  HCV+  and  HCV-  kidney 
transplant  recipients
(8).  Also,  Lee  et  al, 
reported  that  graft  looses  and  death  rates 
were  not  significantly  different  between 
HCV+  and  HCV-  kidney  recipients
(9).  In 
contrast,  Legendre  et  al,  Gentil  et  al,  and 
Bruchfeld  et  al,  observed  a  significantly 
higher  percentage  of  graft  loss  among 
HCV+  than  HCV-  renal  recipients
(10,11,7). 
Batty et al, claimed a 13% mortality rate in 
HSV+  and  8.5%  in  HCV-  patients
(12). 
Nevertheless,  Bezard-Behbahani  et  al, 
evaluated  the  impact  of  HCV  infection 
occurring  after  kidney  transplantation,  and 
they  suggested  that  HCV  infection  (in  a 
previously  HCV-  recipient  before  transp-
lantation)  did  not  cause  or  contribute  to 
renal  dysfunction  during  the  one  year 
follow-up  period  of  the  study
(13).  The 
frequency  of  new  onset  DM  was  signifi-
cantly higher in HCV+ (19.4%) than HCV- 
(8.7%)  patients.  A  similar  finding  was 
observed by Stehman - Breen et al,
 resulting 
in  18%  prevalence  of  DM  in  an  HCV 
infection  cohort
(14).  There  was  unexplained 
statistically  insignificant  higher  incidence 
of delayed graft function among HCV- than 
HCV+ group. On the other hand, there was 
a significant (P<0.05) increased number of 
acute  rejection  episodes  among  HCV+ 
(11=30.6%) compared to HCV- (5=10.9%) 
recipients.  This  study  showed  a  signifi-
cantly  increased  incidence  of  cytome-
galovirus disease in group II (11.1%) with a 
RR 5.1 in comparison to HCV- group. Till 
publishing this work, there were no trials in 
the  literature  correlating  HCV  status  and 
cytomegalovirus  disease  after  kidney 
transplantation. 
 
Conclusion& Recommendations 
 
  This  study  suggested  that  HCV 
infection  among  ESRD  patients  does  not 
affect significantly  patient  and  renal  allog-
raft  survival  after  kidney  transplantation 
despite  the  significant  increased  incidence 
of  acute  rejection  episodes  and  cytome-
galovirus  disease  during  the  first  3  years 
following transplantation. A more extended 
study is advisable to identify the impact of 
HCV infection on the long term patient and 
graft  survival.  Lastly,  all  measures  should 
be  taken  to  prevent  HCV  transmission  in 
dialysis population. 
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 يدبكلا باهتللاا سوريف يودع رثا ( ًس  ) ًلكلا ةعارز ًلع  
ناميلس رساي  
 تٍطابلا هظق –    بطلا تيمك -   ضىش ًيع تعواج  
 
 ٕااطْزي لا ٖيااب لا كاااّالتا  ت اااصلإا يا  ( ٕااط  )  ٕاا زو ٕااا تااقاعلإاْ ثااايآلا ثتيااعو ًااو ياايشي
 ٕام لا تاعارس  .  ٔيااب ل صْزي لاا  يٓ اابىلا ٕاا زىلا يا  ( ٕاط  ) ع زااركك يٓآٌ ي  ًااو َااآمل تا ز
 ٕام لا  رس هاّل ًيذلا ٕ زىلا  . اطرايلا َذاِ ًاو  ياّلا يا ت   اطارر ٓاِ ت    صْزي لاا  ت ااصلإا زييثات
( ٕااط  )   رشاالا تاايمىع يااع  تاالٓ ٍىلا ٕاام لا ٕاامعْ ٕاا زىلا ٕاامع .  تااطاريلا َذااِ ًىااضات 82     اااضيزو
 ٕاام لا تااعارس تاايمىع هااّل هاات ًيذاالاْ ًوشااىلا ٔٓاام لا كاا     ا ااابو  . ىلا هيااظ ت هاات يااقْ  ٕاالا ٕاا ز
 ًياعٓىجو :  -
 ًلولاا ةعىمجملا : -    ًىضات 64    ٖيب لا صْزي لا  ًي ابو زيغ  اضيزو  ( ٕط  )  
 ةيناثلا ةعىمجملا : -    ًىضات 64    صْزي لا   ًي ابو  اضيزو (  ٕط  )  ت اجا  كلذ ٕمع لياطاْ
 ُيا يا رلإاْ ةراضىلا ناظجتا  . ٓىجىلا ٕا كياىاو تعاٍىمل ظبرىلا ٕئاْيلا لٓكٓتْزبلا ياكْ  ًياع
 ةيىل ٕ زىلا تع ااو هت يقْ 6    ثآٍط .  
            ٓاٌْ ضٍاجلاْ زاىعمل تبظٍلا  ًياعٓىجىلا ًي  تيئابحإ تلتر ُل ضيل قزا تطاريلا ثزّظك
  زباىلا  (  كالذ زيغ ْا ٕ زىمل بيزق .  ةياىل تباظٍلا  تاىي لا تايلاع تيئاابحإ ُالتر دئاااٍلا ثزاّظكْ
يح ،  رشلا تيمىع كبق ٔٓويلا ءا باطتا  لٓاطا ٔٓويالا ءا اباطتا ةيو يا يجْ ث  ( 6.4   ±    6.3  
 )  صزي لا  ًي ابىلا ٕ زىلا ٕا ( ٕاط  )  صْزي لاا  ًي اابو زايرلا ٕا زىلا  ُاٌرا و ( ٕاط  ( ) 8.6  
±    6.6    .  )  تاعٓىجو كاك ًاو ٕا زىلا ٔيحا ةاآل تيئابحا ُلتر ْذ دئااٌ زّظت هل  , ,  هال ااضي ك
 ًيٍيلإ تيئابحإ تلتر ْذ دئااٌ زّظت ( 6.6    )%  ت اابىلا تاعٓىجىلا ٕاا ٕام لا تاعارس ٕا زو ًاو
 صزااي   ( ٕااط  )  تاايلاي ْ ( 2.6    )%  صزااي   ت ااابىلا تااعٓىجىلا ٕاااا ( ٕاااط  )  ٓاااضعلا ياياا  ل كاالذ ْ
  ْرشىلا 0   ياصك ياق ْ ب    ٕام لا تا يظْ ٕاا زخثاا   رشالا تايمىع هاّل هات ًيذالا ٕا زىلا ًاو تاظىخ
 ٕاالْ ا تااعٓىجىلا ًااو تااعْرشىلا ( 90.4    )% اا  تااٌرا ىلا  كاالذ ْ  ًيٍيإ  ( 6.4    )%  تااعٓىجىلا ًااو
 تيئاابحإ ُالتر ُال ضيال قز لا ً لْ تيٌارلا .   ازالا ثاايمىع ًاو زابكا رياع رٓاجْ دئاااٍلا ثزاّظك
 ٔيااب لا صْزي لااا  ًي ااابىلا ٕاا زىمل تااعْرشىلا ٕاام مل راااحلا  ( ٕااط   %( ) 60.4    = 99  )  كاالذْ
 صْزي لاااا  ًي اااابو زااايرلا ٕااا زىلا  تاااٌرا ىلا   ( ٕاااط  % ( ) 90.4    = 6    ) اذاااِْ    ُااالتر ْذ قزااا لا
 ًي اابىلا ٕا زىلا ًيا  ثيياح ٔز اظلا لٓابلا لزاو ثتااح ثازاّظ ياقْ تاىي لا تايلاع تيئابحا
 ٕااطْزي لا ٔيااب لا كاااّالتا  (  ٕااط  ( ) 94.6      )%  ٕااا ٔٓوياالا ءا ااباطتا تاايمىع هااّل هاااي ًيذاالاْ
 تيئابحإ ُلتر ُل ضيل قز لا ً لْ ٕم لا  ارس تيمىع راظاٌا .  اضيا دئااٍلا ثزّظك  ْذ قزاا رٓاجْ
ٓلاجوٓاياظلا صْزاايا لزاى  ت اااصت تاظٍلا   تااٌاوا ُالتر    ٕاا زىلا ٕااا ٕامعا تبااظٌ رٓاجٓ  كاالذْ
 صْز لا  ًي ابىلا  ( ٕط ( ) 99.9    ) %  صْزي لاا  ًي اابو زيرلا ٕ زىلا  تٌرا ىلا  ( ٕاط  ( ) 8.8  
 ) %   رشلا تيمىع هّل هت ًيذلاْ  
 تايصىتلا : -     صْزي لا  ت اصلإا يا دئااٍلا ثزّظك ( ٕط  )  َااجٌ ًاو كاك ٕمع ح اْ ك     زيٓيت
 لياعو ٕاا ةراايس رٓاجْ ًاو هغزالا ٕامع كالذْ ٕم لا تعارس تيمىع يع   ْرشىلا ٓضعلاْ ٕ زىلا
ٓلاجوٓايظلا صْزيا لزى  ت اصلإاْ تعْرشىلا ٕم مل راحلا  ازلا ثتاح .  
 ٔيب لا صْزي لا ٕ زو را اٌا عٍىل ثاءازجلإا كك ذاختا بجي ازيخك ْ  ( ٕط  ) ًي     ٕ زو
ٔٓويلا ءا باطتا  